BAX…if another [disease-modifying] drug launched, gammagard could not compete on price. it would need to be much more effective to get payors to cover.
What’s the likelihood that two disease-modifying agents for AD will be approved in the next few years? It must be pretty darn small.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”